| Literature DB >> 27070704 |
Elizabeth C Townsend1, Mark A Murakami1, Alexandra Christodoulou1, Amanda L Christie1, Johannes Köster2, Tiffany A DeSouza1, Elizabeth A Morgan3, Scott P Kallgren4, Huiyun Liu1, Shuo-Chieh Wu1, Olivia Plana1, Joan Montero1, Kristen E Stevenson5, Prakash Rao6, Raga Vadhi6, Michael Andreeff7, Philippe Armand1, Karen K Ballen8, Patrizia Barzaghi-Rinaudo9, Sarah Cahill1, Rachael A Clark10, Vesselina G Cooke9, Matthew S Davids1, Daniel J DeAngelo1, David M Dorfman3, Hilary Eaton11, Benjamin L Ebert12, Julia Etchin13, Brant Firestone9, David C Fisher1, Arnold S Freedman1, Ilene A Galinsky1, Hui Gao9, Jacqueline S Garcia1, Francine Garnache-Ottou14, Timothy A Graubert8, Alejandro Gutierrez15, Ensar Halilovic9, Marian H Harris16, Zachary T Herbert17, Steven M Horwitz18, Giorgio Inghirami19, Andrew M Intlekofer18, Moriko Ito9, Shai Izraeli20, Eric D Jacobsen1, Caron A Jacobson1, Sébastien Jeay9, Irmela Jeremias21, Michelle A Kelliher22, Raphael Koch1, Marina Konopleva7, Nadja Kopp1, Steven M Kornblau7, Andrew L Kung23, Thomas S Kupper10, Nicole R LeBoeuf10, Ann S LaCasce1, Emma Lees9, Loretta S Li13, A Thomas Look13, Masato Murakami9, Markus Muschen24, Donna Neuberg5, Samuel Y Ng1, Oreofe O Odejide1, Stuart H Orkin13, Rachel R Paquette25, Andrew E Place13, Justine E Roderick22, Jeremy A Ryan1, Stephen E Sallan13, Brent Shoji26, Lewis B Silverman13, Robert J Soiffer1, David P Steensma1, Kimberly Stegmaier13, Richard M Stone1, Jerome Tamburini27, Aaron R Thorner25, Paul van Hummelen25, Martha Wadleigh1, Marion Wiesmann9, Andrew P Weng28, Jens U Wuerthner9, David A Williams23, Bruce M Wollison25, Andrew A Lane1, Anthony Letai1, Monica M Bertagnolli24, Jerome Ritz1, Myles Brown2, Henry Long2, Jon C Aster3, Margaret A Shipp1, James D Griffin1, David M Weinstock29.
Abstract
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27070704 PMCID： PMC5177991 DOI： 10.1016/j.ccell.2016.03.008
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743